---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-059379"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2021-12-06T23:59:59+00:00"
generated_at: "2026-06-28T03:33:02.788086+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics reports interim Phase 1/2 BDC-1001 data: safe, 1 durable PR at 52 weeks, no CRS

## Summary
- BDC-1001 showed favorable safety in 57 patients; no dose-limiting toxicities up to 20 mg/kg Q3W and 12 mg/kg Q2W.
- One durable partial response maintained through 52 weeks; multiple patients with stable disease >12 weeks in 40 evaluable subjects.
- No cytokine release syndrome (CRS) observed; maximum tolerated dose not yet reached.
- Plasma/tissue biomarkers confirm TLR7/8 activation and myeloid cell infiltration consistent with mechanism of action.
- Company plans to continue monotherapy dose escalation, evaluate weekly dosing, and initiate combination with nivolumab by year-end 2021.

## SEC filing metadata
- accession: 0001564590-21-059379
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2021-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000156459021059379/0001564590-21-059379-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000156459021059379/bolt-8k_20211206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-059379
- JSON: https://secwatch.observer/filing/0001564590-21-059379.json
- Plain text: https://secwatch.observer/filing/0001564590-21-059379.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.